相关临床试验
17
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
11.8%
已完成
5
29.4%
招募中
5
29.4%
终止
4
23.5%
撤回
1
5.9%
暂无批准数据
- Cardurion Pharmaceuticals will present Phase 2 CYCLE trial results for tovinontrine (CRD-750), a novel PDE9 inhibitor, at the HFSA Annual Scientific Meeting in Phoenix, Arizona, October 9–12, 2026. - Tovinontrine is an orally administered PDE9 inhibitor that enhances the natriuretic peptide signaling pathway, and Cardurion is the first company to bring a PDE9 inhibitor into clinical development for chronic heart failure. - The global, multi-center Phase 2 trials (NCT06215911 and NCT06215586) assess safety and efficacy in both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). - Despite current standard of care, a large unmet need remains, as approximately 6.7 million U.S. adults have heart failure and about 50 percent die within five years of diagnosis.
- Strand Therapeutics has appointed former Nimbus Therapeutics CEO Jeb Keiper as an independent board director to strengthen business development capabilities as the company scales its programmable mRNA platform. - Keiper brings extensive biotech leadership experience, having overseen four clinical programs at Nimbus, raised over $650 million in funding, and executed deals worth over $7 billion during his tenure. - The appointment follows Strand's strong 2025 momentum, including a $153 million Series B financing and positive Phase 1 data for lead candidate STX-001 showing clinical responses in advanced solid tumor patients. - Strand's programmable mRNA platform uses synthetic biology to enable logic-controlled expression and precision delivery, with ongoing trials in solid tumors and expansion into CAR-T therapy planned.
- Cardurion Pharmaceuticals has completed enrollment in two Phase 2 trials evaluating CRD-750, the first clinical-stage PDE9 inhibitor for chronic heart failure treatment. - The CYCLE trials enrolled approximately 860 patients across both heart failure subtypes, with CYCLE-1-REF testing three doses in 560 HFrEF patients and CYCLE-2-PEF evaluating one dose in 300 HFpEF patients. - CRD-750 targets phosphodiesterase 9 inhibition to enhance natriuretic peptide signaling, addressing a significant unmet medical need in heart failure where 50% of patients die within five years of diagnosis. - The trials use NT-proBNP reduction as the primary endpoint, a validated biomarker previously used in approved heart failure therapies, with results expected to be presented at future medical meetings.
- Cardurion Pharmaceuticals has been named one of the Endpoints 11 most promising private biotechnology companies of 2024, recognizing its innovative approach to cardiovascular disease treatment. - The company's clinical programs include CRD-750, a PDE9 inhibitor in Phase 2 trials for chronic heart failure, and CRD-4730, a CaMKII inhibitor in Phase 2 for catecholaminergic polymorphic ventricular tachycardia (CPVT). - Cardurion is focused on developing next-generation therapeutics targeting unmet needs in cardiovascular diseases, which remain a leading cause of death globally. - The recognition highlights Cardurion's strengths in science, leadership, investors, and strategy in developing novel cardiovascular therapeutics.
